Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18739680 | KIT, DEVICE, AND METHOD FOR DETECTING LUNG CANCER | June 2024 | June 2025 | Allow | 13 | 1 | 1 | No | No |
| 18646971 | Kit for Assaying AFP mRNA for Liver Cancer Diagnosis | April 2024 | January 2025 | Abandon | 8 | 1 | 0 | No | No |
| 18614496 | METHOD OF MEASURING CHIMERISM | March 2024 | May 2025 | Abandon | 14 | 0 | 1 | No | No |
| 18444053 | METHODS FOR EARLY PREDICTION, TREATMENT RESPONSE, RECURRENCE AND PROGNOSIS MONITORING OF PANCREATIC CANCER | February 2024 | November 2024 | Allow | 9 | 1 | 1 | Yes | No |
| 18422247 | ASSAYS FOR FUNGAL INFECTION | January 2024 | July 2025 | Allow | 17 | 1 | 1 | Yes | No |
| 18421579 | ASSAYS FOR FUNGAL INFECTION | January 2024 | April 2025 | Allow | 14 | 1 | 0 | No | No |
| 18408056 | KIT, DEVICE AND METHOD FOR DETECTING PROSTATE CANCER | January 2024 | January 2025 | Allow | 12 | 1 | 1 | No | No |
| 18504402 | COMBINATIONS, DETECTION METHODS AND KITS OF DNA METHYLATION BIOMARKER | November 2023 | July 2025 | Allow | 20 | 1 | 1 | Yes | No |
| 18500680 | PREPARATION OF TEMPLATES FOR METHYLATION ANALYSIS | November 2023 | April 2025 | Allow | 17 | 1 | 1 | Yes | No |
| 18350566 | HIGHLY STABLE AND SPECIFIC MOLECULAR BEACONS ENCAPSULATED IN CATIONIC LIPOPLEX NANOPARTICLES AND APPLICATION THEREOF | July 2023 | December 2024 | Abandon | 17 | 0 | 1 | No | No |
| 18302737 | BREAST CANCER SPLICE VARIANTS | April 2023 | April 2025 | Abandon | 24 | 2 | 1 | No | No |
| 18165089 | DEVICES AND METHODS FOR MOLECULE DETECTION BASED ON THERMAL STABILITIES OF MAGNETIC NANOPARTICLES | February 2023 | August 2024 | Allow | 18 | 1 | 1 | No | No |
| 18083221 | METHODS FOR PROSTATE CANCER DETECTION | December 2022 | January 2025 | Allow | 26 | 2 | 1 | Yes | No |
| 18067661 | MULTIMODAL ANALYSIS OF CIRCULATING TUMOR NUCLEIC ACID MOLECULES | December 2022 | June 2025 | Abandon | 30 | 2 | 1 | Yes | No |
| 17991739 | METHODS AND SYSTEMS FOR DETECTING TISSUE CONDITIONS | November 2022 | December 2024 | Abandon | 24 | 1 | 1 | No | No |
| 18050855 | METHODS AND SYSTEMS FOR IMPROVING PATIENT MONITORING AFTER SURGERY | October 2022 | January 2024 | Abandon | 15 | 2 | 1 | Yes | No |
| 17960026 | CUSTOMIZED ASSAYS FOR PERSONALIZED CANCER MONITORING | October 2022 | January 2025 | Allow | 27 | 3 | 1 | Yes | No |
| 17817452 | BIOMARKERS FOR HEAD AND NECK CANCER AND METHODS OF THEIR USE | August 2022 | January 2025 | Allow | 30 | 2 | 1 | Yes | No |
| 17812415 | OPTIMIZATION OF MULTIGENE ANALYSIS OF TUMOR SAMPLES | July 2022 | August 2024 | Allow | 25 | 1 | 1 | No | No |
| 17810816 | Methods Of Treating Skin Cancer With Histidine Ammonia-Lyase (HAL) Agonists | July 2022 | August 2024 | Allow | 26 | 1 | 1 | Yes | No |
| 17837731 | UNBIASED DNA METHYLATION MARKERS DEFINE AN EXTENSIVE FIELD DEFECT IN HISTOLOGICALLY NORMAL PROSTATE TISSUES ASSOCIATED WITH PROSTATE CANCER: NEW BIOMARKERS FOR MEN WITH PROSTATE CANCER | June 2022 | November 2024 | Allow | 29 | 4 | 1 | Yes | No |
| 17751201 | Methods and Processes for Non-Invasive Assessment of Genetic Variations | May 2022 | July 2024 | Allow | 26 | 1 | 1 | Yes | No |
| 17743698 | Methods of Detecting Trichomonas Vaginalis | May 2022 | September 2024 | Allow | 29 | 2 | 1 | Yes | No |
| 17713143 | Method of Determining and Treating Breast Cancer | April 2022 | February 2025 | Allow | 34 | 2 | 1 | Yes | No |
| 17694306 | BCR-ABL VARIANTS | March 2022 | July 2024 | Allow | 28 | 2 | 1 | Yes | No |
| 17561077 | PROCESSES, MACHINES, AND COMPOSITIONS RELATED TO ANALYZING NEOPLASMS SUCH AS CANCER | December 2021 | November 2023 | Abandon | 23 | 2 | 1 | No | No |
| 17554966 | METHODS AND COMPOSITIONS FOR PROGNOSIS AND TREATMENT OF CANCERS | December 2021 | June 2025 | Allow | 42 | 2 | 1 | No | No |
| 17616149 | Methods and Kits for Detection of N-4-acetyldeoxycytidine in DNA | December 2021 | May 2025 | Abandon | 41 | 0 | 1 | No | No |
| 17527576 | Polymerase Chain Reaction Primers and Probes for Mycobacterium Tuberculosis | November 2021 | July 2024 | Allow | 32 | 3 | 1 | Yes | No |
| 17523325 | METHODS FOR ASSESSING THE PURITY OF A MESENCHYMAL STEM CELLS PREPARATION | November 2021 | January 2025 | Abandon | 38 | 2 | 1 | No | No |
| 17504058 | WHOLE-GENOME HAPLOTYPE RECONSTRUCTION | October 2021 | August 2024 | Allow | 34 | 1 | 1 | No | No |
| 17602161 | SAMPLE ANALYSIS DEVICE | October 2021 | April 2025 | Allow | 42 | 2 | 0 | Yes | No |
| 17494465 | METHODS AND COMPOSITIONS FOR SYNTHETIC BIOMARKERS | October 2021 | June 2025 | Abandon | 44 | 0 | 1 | No | No |
| 17481374 | SSB METHOD | September 2021 | April 2025 | Allow | 43 | 3 | 1 | Yes | No |
| 17459477 | SELECTION AND TREATMENT OF CANCER WITH COMBINATION THERAPIES | August 2021 | December 2024 | Abandon | 40 | 3 | 1 | No | No |
| 17395244 | METHOD FOR IDENTIFYING HIGH-RISK AML PATIENTS | August 2021 | June 2025 | Abandon | 47 | 1 | 1 | No | No |
| 17310116 | SCREENING METHOD | July 2021 | June 2025 | Abandon | 47 | 0 | 1 | No | No |
| 17357862 | HIGHLY STABLE AND SPECIFIC MOLECULAR BEACONS ENCAPSULATED IN CATIONIC LIPOPLEX NANOPARTICLES AND APPLICATION THEREOF | June 2021 | August 2024 | Allow | 38 | 1 | 1 | Yes | No |
| 17415747 | METHOD FOR SIMULTANEOUSLY DETECTING EXOSOME MEMBRANE PROTEIN AND MRNA | June 2021 | February 2025 | Abandon | 44 | 1 | 0 | No | No |
| 17349734 | METHODS FOR ANALYSIS OF CELL-FREE RNA | June 2021 | March 2025 | Abandon | 45 | 3 | 1 | No | No |
| 17413173 | MIRNAS AS BIOMARKERS FOR PARKINSON'S SYNDROME | June 2021 | April 2025 | Abandon | 46 | 1 | 1 | No | No |
| 17311442 | COMPOSITIONS AND METHODS FOR DETECTION OF CANDIDA AURIS | June 2021 | February 2025 | Allow | 45 | 1 | 1 | No | No |
| 17286483 | PROBE HAVING OCTAMINE OR OCTAMINE DERIVATIVE BOUND THERETO, AND USES OF SAME | April 2021 | November 2024 | Abandon | 43 | 1 | 0 | No | No |
| 17231725 | METHODS AND SYSTEMS FOR TARGET SCREENING | April 2021 | February 2025 | Abandon | 46 | 1 | 1 | Yes | No |
| 17282305 | METHODS AND COMPOSITIONS FOR HIGH SENSITIVITY DETECTION OF DRUG RESISTANCE MARKERS | April 2021 | June 2025 | Abandon | 51 | 0 | 2 | No | No |
| 17206895 | BIOMARKERS OF RESPONSE TO HIF-2-ALPHA INHIBITION IN CANCER AND METHODS FOR THE USE THEREOF | March 2021 | August 2024 | Allow | 41 | 2 | 1 | No | No |
| 17263708 | METHOD OF MONITORING EFFECTIVENESS OF IMMUNOTHERAPY OF CANCER PATIENTS | January 2021 | June 2025 | Abandon | 52 | 4 | 1 | No | No |
| 17257991 | TRANSPOSOME ENABLED DNA/RNA-SEQUENCING (TED RNA-SEQ) | January 2021 | November 2024 | Abandon | 46 | 2 | 0 | No | No |
| 15734363 | METHODS FOR DEVELOPING URINE BIOMARKERS AND FOR DETECTING BLADDER CANCER | December 2020 | April 2025 | Allow | 52 | 1 | 1 | Yes | No |
| 17054204 | MOLECULAR GENE SIGNATURES AND METHODS OF USING SAME | November 2020 | September 2024 | Allow | 46 | 1 | 1 | No | No |
| 17053688 | METHODS FOR EARLY PREDICTION, TREATMENT RESPONSE, RECURRENCE AND PROGNOSIS MONITORING OF BREAST CANCER | November 2020 | November 2024 | Allow | 48 | 3 | 1 | Yes | No |
| 16929512 | RADIATION BIODOSIMETRY SYSTEMS | July 2020 | January 2025 | Abandon | 54 | 4 | 1 | No | No |
| 16954370 | COMPOSTIONS AND METHODS FOR DIAGNOSING LUNG CANCERS USING GENE EXPRESSION PROFILES | June 2020 | October 2024 | Allow | 52 | 5 | 1 | Yes | No |
| 16859655 | IDENTIFICATION OF POLYMORPHIC SEQUENCES IN MIXTURES OF GENOMIC DNA | April 2020 | June 2025 | Allow | 60 | 2 | 1 | No | No |
| 16650849 | RISK DETERMINATION FOR NEOPLASIA AND CANCER | March 2020 | February 2025 | Allow | 59 | 6 | 1 | No | No |
| 16637372 | METHODS AND MATERIALS FOR ASSESSING AND TREATING CANCER | February 2020 | August 2024 | Allow | 54 | 4 | 1 | Yes | No |
| 16428735 | PRODUCTS AND PROCESSES FOR NUCLEIC ACID DETECTION AND QUANTIFICATION | May 2019 | August 2024 | Allow | 60 | 4 | 1 | No | No |
| 16342758 | HIGH RESOLUTION SPATIAL GENOMIC ANALYSIS OF TISSUES AND CELL AGGREGATES | April 2019 | August 2024 | Allow | 60 | 4 | 1 | Yes | No |
| 16309271 | COMPOSITIONS AND METHODS FOR DETECTION OF NUCLEIC ACID MUTATIONS | December 2018 | June 2025 | Abandon | 60 | 6 | 1 | Yes | No |
| 16099451 | METHODS FOR CLASSIFYING PATIENTS WITH A SOLID CANCER | November 2018 | August 2024 | Abandon | 60 | 7 | 1 | Yes | No |
| 16098455 | CELL-FREE DETECTION OF METHYLATED TUMOUR DNA | November 2018 | April 2025 | Allow | 60 | 7 | 2 | Yes | No |
| 16016460 | METHODS AND COMPOSITIONS FOR THE ANALYSIS OF CANCER BIOMARKERS | June 2018 | January 2025 | Allow | 60 | 7 | 1 | Yes | No |
| 15730382 | N-ACETYL-alpha-D-GLUCOSAMINIDASE DEFICIENCY COMPOSITIONS AND METHODS | October 2017 | January 2020 | Allow | 27 | 2 | 1 | No | No |
| 15520990 | BIOMARKERS FOR PREDICTING WEIGHT LOSS AND WEIGHT MAINTENANCE | April 2017 | February 2020 | Allow | 34 | 3 | 1 | Yes | No |
| 15502418 | MICRORNAS CHARACTERIZING ACNE AND THE USES THEREOF | February 2017 | January 2020 | Allow | 35 | 3 | 1 | Yes | No |
| 15201302 | METHOD FOR HIGH SENSITIVITY DETECTION OF MYD88 MUTATIONS | July 2016 | October 2018 | Allow | 28 | 1 | 1 | Yes | No |
| 14801304 | PREDICTION AND PROPHYLACTIC TREATMENT OF TYPE 1 DIABETES | July 2015 | March 2018 | Allow | 32 | 2 | 0 | No | No |
| 14413659 | Therapeutic Targets for Alzheimer's Disease | January 2015 | November 2017 | Allow | 35 | 3 | 1 | Yes | No |
| 14302199 | RECURRENT GENE FUSIONS IN PROSTATE CANCER | June 2014 | October 2017 | Allow | 40 | 5 | 1 | Yes | No |
| 13641444 | REAL TIME PCR ASSAY FOR DETECTION OF BACTERIAL RESPIRATORY PATHOGENS | November 2012 | October 2015 | Allow | 36 | 2 | 1 | Yes | No |
| 13127934 | BIFIDOBACTERIA CRISPR SEQUENCES | August 2011 | April 2017 | Abandon | 60 | 8 | 1 | Yes | No |
| 13006619 | ASSOCIATION OF EDG5 POLYMORPHISM V286A WITH TYPE II DIABETES MELLITUS AND VENOUS THROMBOSIS/PULMONARY EMBOLISM AND THE USE THEREOF | January 2011 | March 2012 | Allow | 14 | 1 | 1 | Yes | No |
| 12999201 | COMPOSITIONS AND METHODS FOR PROGNOSIS OF OVARIAN CANCER | December 2010 | August 2016 | Allow | 60 | 5 | 1 | Yes | No |
| 12994751 | PRIMER AND PROBE FOR DETECTION OF MYCOBACTERIUM INTRACELLULARE, AND METHOD FOR DETECTION OF MYCOBACTERIUM INTRACELLULARE USING THE PRIMER OR THE PROBE | November 2010 | March 2019 | Allow | 60 | 11 | 1 | Yes | No |
| 12910454 | OLIGONUCLEOTIDE SEQUENCE FORMULA FOR LABELING OLIGNUCLEOTIDE PROBES AND PROTEINS FOR IN-SITU ANALYSIS | October 2010 | March 2012 | Allow | 17 | 1 | 1 | Yes | No |
| 12294915 | PROBE, PROBE SET, PROBE-IMMOBILIZED CARRIER, AND GENETIC TESTING METHOD | September 2010 | November 2012 | Allow | 50 | 2 | 1 | Yes | No |
| 12882533 | RECURRENT GENE FUSIONS IN PROSTATE CANCER | September 2010 | August 2017 | Allow | 60 | 7 | 2 | Yes | No |
| 12864218 | SINGLE NUCLEOTIDE POLYMORPHISMS ASSOCIATED WITH RENAL DISEASE | July 2010 | March 2015 | Allow | 56 | 4 | 1 | Yes | No |
| 12601763 | METHOD TO PREDICT OR DIAGNOSE A GASTROINTESTINAL DISORDER OR DISEASE | April 2010 | April 2019 | Allow | 60 | 8 | 1 | Yes | Yes |
| 12529701 | CANCER ANTIGEN-SPECIFIC T-CELL RECEPTOR GENE, PEPTIDE ENCODED BY THE GENE, AND USE OF THEM | March 2010 | December 2015 | Allow | 60 | 8 | 2 | Yes | No |
| 12294912 | PROBE, PROBE SET, PROBE-IMMOBILIZED CARRIER, AND GENETIC TESTING METHOD | January 2010 | February 2012 | Allow | 41 | 0 | 0 | No | No |
| 12294914 | PROBE, PROBE SET, PROBE-IMMOBILIZED CARRIER, AND GENETIC TESTING METHOD | January 2010 | October 2011 | Allow | 37 | 1 | 1 | Yes | No |
| 12620187 | DETECTION OF METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS | November 2009 | March 2012 | Allow | 28 | 2 | 1 | Yes | No |
| 12586862 | CHROMOSOME 1P36 POLYMORPHISMS AND LOW BONE MINERAL DENSITY | September 2009 | July 2011 | Allow | 22 | 1 | 1 | Yes | No |
| 12554141 | OSTEOARTHRITIS BIOMARKERS AND USES THEREOF | September 2009 | October 2011 | Allow | 25 | 0 | 0 | Yes | No |
| 12295584 | PROBE, PROBE SET, PROBE-IMMOBILIZED CARRIER, AND GENETIC TESTING METHOD | August 2009 | October 2011 | Allow | 37 | 2 | 1 | Yes | No |
| 12295274 | PROBE, PROBE SET, PROBE-IMMOBILIZED CARRIER, AND GENETIC TESTING METHOD | August 2009 | October 2011 | Allow | 37 | 2 | 1 | Yes | No |
| 12294910 | PROBE, PROBE SET, PROBE-IMMOBILIZED CARRIER, AND GENETIC TESTING METHOD | August 2009 | March 2012 | Allow | 42 | 2 | 1 | Yes | No |
| 12295273 | PROBE, PROBE SET, PROBE-IMMOBILIZED CARRIER, AND GENETIC TESTING METHOD | March 2009 | October 2011 | Allow | 37 | 1 | 1 | Yes | No |
| 12295579 | PROBE, PROBE SET, PROBE-IMMOBILIZED CARRIER, AND GENETIC TESTING METHOD | February 2009 | December 2011 | Allow | 39 | 3 | 1 | Yes | No |
| 12323861 | POLYMORPHISMS OF THE BLYS GENE AND USE IN DIAGNOSTIC METHODS | November 2008 | February 2011 | Allow | 26 | 1 | 1 | Yes | No |
| 12272265 | PREDICTING AND DIAGNOSING PATIENTS WITH AUTOIMMUNE DISEASE | November 2008 | February 2011 | Allow | 27 | 1 | 1 | Yes | No |
| 12147171 | METHODS AND COMPOSITIONS FOR CORRELATING GENETIC MARKERS WITH MULTIPLE SCLEROSIS | June 2008 | December 2011 | Allow | 41 | 3 | 1 | Yes | No |
| 11935722 | PROBE, PROBE SET, PROBE-IMMOBILIZED CARRIER, AND GENETIC TESTING METHOD | November 2007 | March 2012 | Allow | 52 | 4 | 1 | Yes | No |
| 11861075 | SULFOTRANSFERASE 1E1 SEQUENCE VARIANTS | September 2007 | May 2010 | Allow | 32 | 2 | 0 | Yes | No |
| 11861065 | SULFOTRANSFERASE 2B1 PHARMACOGENETICS | September 2007 | June 2010 | Allow | 33 | 2 | 0 | Yes | No |
| 11834998 | ASSOCIATION OF EDG5 POLYMORPHISM V286A WITH TYPE II DIABETES MELLITUS AND VENOUS THROMBOSIS/PULMONARY EMBOLISM AND THE USE THEREOF | August 2007 | September 2010 | Allow | 38 | 2 | 0 | Yes | Yes |
| 11825552 | Recurrent gene fusions in prostate cancer | July 2007 | January 2018 | Allow | 60 | 8 | 2 | Yes | No |
| 11544065 | METHOD TO PREDICT THE RESPONSE TO LITHIUM TREATMENT | October 2006 | November 2010 | Allow | 49 | 5 | 1 | Yes | No |
| 11538073 | MARKER FOR TARDIVE DYSKINESIA | October 2006 | November 2009 | Allow | 37 | 2 | 1 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner SALMON, KATHERINE D.
With a 50.0% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is above the USPTO average, indicating that appeals have better success here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 71.4% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the top 25% across the USPTO, indicating that filing appeals is particularly effective here. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
✓ Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
Examiner SALMON, KATHERINE D works in Art Unit 1682 and has examined 105 patent applications in our dataset. With an allowance rate of 77.1%, this examiner has a below-average tendency to allow applications. Applications typically reach final disposition in approximately 42 months.
Examiner SALMON, KATHERINE D's allowance rate of 77.1% places them in the 36% percentile among all USPTO examiners. This examiner has a below-average tendency to allow applications.
On average, applications examined by SALMON, KATHERINE D receive 2.70 office actions before reaching final disposition. This places the examiner in the 90% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.
The median time to disposition (half-life) for applications examined by SALMON, KATHERINE D is 42 months. This places the examiner in the 4% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +41.3% benefit to allowance rate for applications examined by SALMON, KATHERINE D. This interview benefit is in the 90% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 18.7% of applications are subsequently allowed. This success rate is in the 11% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 31.2% of cases where such amendments are filed. This entry rate is in the 37% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.
This examiner withdraws rejections or reopens prosecution in 77.8% of appeals filed. This is in the 65% percentile among all examiners. Of these withdrawals, 57.1% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.
When applicants file petitions regarding this examiner's actions, 73.7% are granted (fully or in part). This grant rate is in the 89% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 16.2% of allowed cases (in the 98% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 3% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.